Promoted Content
Promoted Content

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Country filter
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Bispecific Antibody

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Discovery Platform Product Type: Large molecule

            Partner/Sponsor/Collaborator: Boehringer Ingelheim GmbH

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration October 14, 2020

            Details:

            Boehringer Ingelheim will use OBT’s OGAP® platform to identify novel target opportunities for new immunotherapies utilizing their T-cell engager, cancer vaccine and oncolytic virus platforms.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Undisclosed

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Discovery Platform Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Takara Bio

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement October 12, 2020

            Details:

            PanCELLa agreement marks Merck’s first CRISPR license for bioproduction . Takara Bio USA agreement gives access to Merck’s CRISPR integration and vector technologies for Takara’s vector products and cell engineering services.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): IgM antibodies

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Discovery Platform Product Type: Large molecule

            Partner/Sponsor/Collaborator: IGM Biosciences

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement September 24, 2020

            Details:

            AbCellera will generate panels of antibodies for multiple therapeutic targets identified by IGM using its full-stack and IGM will have the rights to develop and commercialize the novel antibodies resulting from this collaboration.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Bispecific Antibody

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Discovery Platform Product Type: Large molecule

            Partner/Sponsor/Collaborator: REMD

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration September 16, 2020

            Details:

            In the collaboration, GenScript ProBio allowed REMD to use its SMAB bispecific antibody platform to develop novel cancer immunotherapy drugs. GenScript ProBio will support REMD with the selection and development of bispecific antibody candidates.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Mono- and Bispecific human antibodies

            Therapeutic Area: Oncology Product Name: OmniAb

            Highest Development Status: Discovery Platform Product Type: Large molecule

            Partner/Sponsor/Collaborator: Ligand Pharmaceuticals

            Deal Size: $5.0 million Upfront Cash: $5.0 million

            Deal Type: Acquisition September 10, 2020

            Details:

            The acquisitions are expected to enable Ligand to secure new license agreements with expanded economics as a result of the addition of tools and intellectual property that Ligand can now offer to partners.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Mono- and Bispecific human antibodies

            Therapeutic Area: Oncology Product Name: OmniAb

            Highest Development Status: Discovery Platform Product Type: Large molecule

            Partner/Sponsor/Collaborator: Ligand Pharmaceuticals

            Deal Size: $7.0 million Upfront Cash: Undisclosed

            Deal Type: Acquisition September 10, 2020

            Details:

            The acquisition will strengthen company's OmniAb® technology platform. Potential for two approvals of OmniAb-derived antibodies in 2021 with expected new royalty streams to Ligand.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Undisclosed

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Discovery Platform Product Type: Small molecule

            Partner/Sponsor/Collaborator: Exscientia

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Partnership September 09, 2020

            Details:

            Under this collaboration, Exscientia will use its advanced Centaur Chemist AI platform to design new molecules against project specific targets and Huadong will apply its experimental and managerial capabilities to support Exscientia’s AI design in a rapid closed-loop cycle.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Chinese Hamster Ovary K1 cell

            Therapeutic Area: Oncology Product Name: Chosource

            Highest Development Status: Discovery Platform Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: TrueBinding

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement July 29, 2020

            Details:

            TrueBinding will use Horizon’s cGMP-compliant CHOSOURCE™ platform for the development and commercialization of multiple biotherapeutic products for applications in immuno-oncology and other disease areas with great unmet medical need.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Undisclosed

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Discovery Platform Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Undisclosed

            Deal Size: $85.0 million Upfront Cash: Undisclosed

            Deal Type: Financing July 29, 2020

            Details:

            Financing proceeds support identification of novel therapeutic targets and enable genomic medicine programs across a wide range of therapeutic areas

            Syracuse Biopharma

            • Deals

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): T-cell therapy

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Discovery Platform Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: JW Therapeutics

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Acquisition July 20, 2020

            Details:

            JW Therapeutics has acquired Syracuse Biopharma, which includes the license for Eureka Therapeutics’ ARTEMIS® antibody TCR and solid tumor technology for exclusive use in China and the ASEAN countries.

            PharmaCompass